FBIO vs. ACHV, AGEN, RGLS, DOMH, CRIS, BOLT, SABS, MTEM, AMGN, and GILD
Should you be buying Fortress Biotech stock or one of its competitors? The main competitors of Fortress Biotech include Achieve Life Sciences (ACHV), Agenus (AGEN), Regulus Therapeutics (RGLS), Dominari (DOMH), Curis (CRIS), Bolt Biotherapeutics (BOLT), SAB Biotherapeutics (SABS), Molecular Templates (MTEM), Amgen (AMGN), and Gilead Sciences (GILD). These companies are all part of the "biotechnology" industry.
Fortress Biotech vs.
Fortress Biotech (NASDAQ:FBIO) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, community ranking, earnings, valuation and media sentiment.
Fortress Biotech has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.
In the previous week, Achieve Life Sciences had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 1 mentions for Achieve Life Sciences and 0 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.00 equaled Achieve Life Sciences'average media sentiment score.
Achieve Life Sciences has lower revenue, but higher earnings than Fortress Biotech. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.
Achieve Life Sciences has a net margin of 0.00% compared to Fortress Biotech's net margin of -84.53%. Fortress Biotech's return on equity of 0.00% beat Achieve Life Sciences' return on equity.
Fortress Biotech presently has a consensus price target of $13.67, suggesting a potential upside of 743.62%. Achieve Life Sciences has a consensus price target of $14.80, suggesting a potential upside of 366.88%. Given Fortress Biotech's higher probable upside, equities analysts plainly believe Fortress Biotech is more favorable than Achieve Life Sciences.
96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 33.4% of Fortress Biotech shares are held by insiders. Comparatively, 2.0% of Achieve Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Achieve Life Sciences received 7 more outperform votes than Fortress Biotech when rated by MarketBeat users. Likewise, 70.46% of users gave Achieve Life Sciences an outperform vote while only 63.62% of users gave Fortress Biotech an outperform vote.
Summary
Achieve Life Sciences beats Fortress Biotech on 9 of the 16 factors compared between the two stocks.
Get Fortress Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fortress Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:FBIO) was last updated on 2/22/2025 by MarketBeat.com Staff
